GLP-1 weight-loss boom linked to surge in poison control calls
· Medical Xpressedited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
reputable news agency
proofread
The GIST Add as preferred source
As the use of GLP-1 medications for weight loss surges, so do calls to U.S. poison control centers, according to a new study.
A team led by Jordan Miller of the University of Texas at San Antonio analyzed reports submitted to the National Poison Data System involving GLP-1 drugs before and after the 2021 approval of semaglutide for the treatment of obesity.
Prior to approval, the centers recorded roughly 1,000 to 1,500 cases annually. After mid-2021, call volumes nearly doubled. And by 2023, poison centers logged more than 8,000 GLP-1-related calls.
When researchers examined the increase by specific medication, semaglutide accounted for 64% of all GLP-1-related calls, according to the results.
One researcher called its dominance "staggering," though she noted that the finding aligns with the drug's extensive media attention.
Most of the cases resulted from unintentional dosing or therapeutic errors rather than deliberate misuse.
Two of the most common mistakes were patients injecting semaglutide daily instead of weekly and patients starting at the full dose immediately rather than gradually increasing treatment as recommended.
The majority of cases involved mild gastrointestinal symptoms. However, the proportion of patients referred to a health care facility increased from 23% to 33.5% over the study period.
The authors say many of these errors were preventable and could be reduced through better patient education.
The findings were recently published in the Journal of Medical Toxicology.
Publication details
Jordan Miller et al, National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss, Journal of Medical Toxicology (2026). DOI: 10.1007/s13181-026-01121-z
America's Poison Centers has more on GLP-1s and overdose.
Journal information: Journal of Medical Toxicology
Key medical concepts
Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideMedication ErrorsObesity
Clinical categories
Clinical pharmacologyWeight managementCommon illnesses & Prevention Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: GLP-1 weight-loss boom linked to surge in poison control calls (2026, June 25) retrieved 25 June 2026 from https://medicalxpress.com/news/2026-06-glp-weight-loss-boom-linked.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.